By Philippa Clark, Director of Business Development, One Nucleus
Pitching is often treated as something founders do only when they are raising money, yet in life sciences it has become far more than a fundraising exercise. It has turned into one of the most adaptable tools a company has, influencing how it is perceived, supported and championed long before any investment round begins.
As we head towards Genesis 2025 and the launch of the new Company Showcase stream, I’ve been thinking about how much broader the value of pitching has become. Securing capital will always matter, it is what…
By LimestoneGrey, Chartered Tax Advisers specialising in R&D tax relief
Many companies working within the Med-Tech and life sciences sectors are tackling global challenges such as antimicrobial resistance, ageing populations and chronic disease management. Addressing these complex issues often requires research that extends beyond the UK's borders.
However, as part of major reforms to R&D tax relief, the government has now imposed strict limits on the eligibility of overseas expenditure. The new rules aim to encourage domestic innovation, meaning that, by default, most overseas R…
By Tony Jones, CEO, One Nucleus
It is not difficult to see how challenging recent times have been in raising capital for nascent life science companies no matter where they are located. There have always been regional differences in dynamics and financing cycles, but these have to some degree been overshadowed more recently, with almost every location seeing entrepreneurs and leadership teams struggle to secure capital, particularly at the early stages.
Data from the BIA
The latest BIA BioFinancing Report covering July-September 2025 did not necessarily offer much comfort, as one of…
Labs using AI in their supply chains are seeing serious gains. Think a 35% reduction in inventory levels, 15% lower logistics costs, and $300 million in savings by predicting stock risks before they happen. The secret? Smart automation.
Artificial intelligence (AI) is transforming how life science labs manage procurement, from forecasting inventory needs to streamlining vendor selection. Tasks that once required hours of manual effort, like comparing prices, coordinating orders, and pulling spend information, can now be done in minutes.
As the biotech and pharma landscape becomes increasingly…
Breast cancer continues to affect millions worldwide, not just as statistics, but as mothers, sisters, daughters, and friends. Its biological complexity and diverse subtypes make therapy development especially challenging, particularly for metastatic disease, the leading cause of breast cancer mortality.
BioDuro’s CDX (Cell-Derived Xenograft) model platform offers a comprehensive library of preclinical breast cancer models that reflect real-world tumor heterogeneity. These models enable researchers to:
Investigate metastasis mechanisms in clinically relevant systems
Evaluate targeted…
By Alicia Gailliez, Business Development Manager, One Nucleus
On 10 September 2025, leaders from across the life sciences industry came together for a One Nucleus BioWednesday Breakfast Session, generously hosted by Mission Street at The Press in Foxton alongside Bidwells.
The session explored what it takes for science and technology companies, particularly spin-outs and early-stage ventures, to grow and scale effectively in the UK.
The panel was moderated by Sue Foxley (Bidwells) and comprised:
Dr Nataly Hastings, CEO, Cellestial Health
Dr Michael Murray, CEO, MetalloBio & Principal,…
by Tony Jones, CEO, One Nucleus
Dark Times with Pharma:
There is no escaping that the life science sector news over the past weeks has been somewhat dominated by the concerns and actions raised by major Pharma when announcing the withdrawal or on-hold status of further investments in UK R&D, citing the commercial environment in the UK as the primary reason. A review of the various commentaries would appear to suggest the wider reasons driving such announcements include:
Yes, the commercial environment in the UK when it comes to adoption and pricing of new medicines
A desire to respond…
By Alicia Gailliez, Business Development Manager, One Nucleus
The summer season offers a valuable moment to pause and break from routine. This rest creates space for reflection to contemplate what’s working, what’s not and how to move forward with clarity and renewed purpose.
Late summer and early autumn mark a transition back into an exciting and busy networking and dealmaking period. The initial interactions formed through networking can often act as a springboard to deeper engagement whether that leads to future collaboration, knowledge exchange or future business opportunities.…
One Nucleus is delighted to be rolling out its Going for Gold initiative with our members. A data-driven, personalised approach to increase the precision of the support offered to members in their drive to success.
Over recent times bioentrepreneurs and life science business leaders could be forgiven for starting to feel that chasing investment for their innovation or customers for their services is akin to chasing rainbows and their pots of gold. It has certainly been challenging, but some are succeeding, as set out below when looking at global deal volumes and investment. It is…
There is no doubt that the current financing landscape and resultant company restructures or closures are having a significant impact on those individuals involved. It is not just financing, or lack of, that causes such staff turnover, of course. Business growth can lead to new skills and capacities being prioritised; deal-making such as M&A can equally force change, as indeed can personal circumstances. The reasons a life science company employee can find themselves between jobs can be varied and for negative impacts as well as positive choices. Whatever the reason, staying involved in…